Injectable nanoparticulate olanzapine formulations

Abstract

Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.

1 - 18 . (canceled) 
     
     
         19 . A method of making an injectable nanoparticulate olanzapine composition that produces an intramuscular depot upon administration comprising:
 contacting particles of olanzapine or a salt thereof with at least one surface stabilizer for a time and under conditions sufficient to provide an olanzapine composition having an effective average particle size that results in a therapeutic efficacy of about one week or greater, wherein the effective average particle size is between about 300 nm and about 5000 nm.   
     
     
         20 . The method of  claim 19 , wherein the contacting comprises grinding, wet grinding, homogenizing, or a combination thereof. 
     
     
         21 . (canceled) 
     
     
         22 . The composition of  claim 19 , wherein the effective average particle size of the olanzapine particles is less than about 4900 nm, less than about 4800 nm, less than about 4700 nm, less than about 4600 nm, less than about 4500 nm, less than about 4400 nm, less than about 4300 nm, less than about 4200 nm, less than about 4100 nm, less than about 4000 nm, less than about 3900 nm, less than about 3800 nm, less than about 3700 nm, less than about 3600 nm, less than about 3500 nm, less than about 3400 nm, less than about 3300 nm, less than about 3200 nm, less than about 3100 nm, less than about 3000 nm, less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 nm, less than about 2000 nm, less than about 1900 nm, less than less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, or less than about 400 nm. 
     
     
         23 . A method for the treatment of a subject for disorders of the central nervous system comprising administering to the subject an effective amount of an injectable composition comprising:
 (a) olanzapine nanoparticles having an effective average particle size that results in a therapeutic efficacy of about one week or greater;   (b) at least one surface stabilizer; and   (c) at least one pharmaceutically acceptable carrier;   wherein the effective average particle size is between about 300 nm and about 5000 nm.   
     
     
         24 . (canceled) 
     
     
         25 . The method of  claim 23 , wherein the effective average particle size of the olanzapine particles is less than about 4900 nm, less than about 4800 nm, less than about 4700 nm, less than about 4600 nm, less than about 4500 nm, less than about 4400 nm, less than about 4300 nm, less than about 4200 nm, less than about 4100 nm, less than about 4000 nm, less than about 3900 nm, less than about 3800 nm, less than about 3700 nm, less than about 3600 nm, less than about 3500 nm, less than about 3400 nm, less than about 3300 nm, less than about 3200 nm, less than about 3100 nm, less than about 3000 nm, less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 nm, less than about 2000 nm, less than about 1900 nm, less than less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, or less than about 400 nm. 
     
     
         26 . The method of  claim 23 , wherein the depot releases the olanzapine at therapeutic levels for a period of time from about two to about six weeks. 
     
     
         27 . The method of  claim 23 , wherein the depot releases the olanzapine at therapeutic levels for a period of time from about two to about twelve weeks. 
     
     
         28 . The method of  claim 23 , wherein the depot releases the olanzapine at therapeutic levels for a period of time selected from the group consisting of from about one week to about two weeks, from about one week to about three weeks, from about one week to about four weeks, from about one week to about five weeks, from about one week to about six weeks, from about one week to about seven weeks, from about one week to about eight weeks, from about one week to about nine weeks, from about one week to about ten weeks, from about one week to about eleven weeks, from about one week to about twelve weeks, and combinations thereof. 
     
     
         29 . The method of  claim 23 , wherein the AUC of the olanzapine, when assayed in the plasma of a mammalian subject following injectable administration, is greater than the AUC for a non-nanoparticulate olanzapine formulation, administered at the same dosage. 
     
     
         30 . The method of  claim 29 , wherein the AUC is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC exhibited by the non-nanoparticulate formulation of olanzapine, administered at the same dosage. 
     
     
         31 . The method of  claim 23 , wherein the method is used to treat an indication selected from the group consisting of schizophrenia and related psychoses, bipolar mania, bipolar disorder, seizures, obsessive/compulsive disorders, generalized anxiety disorder, post traumatic distress syndrome, extreme shyness, diabetic nerve pain, smoking cessation, and depression.